miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker

Feng Li,1,* Feiran Wang,2,* Changlai Zhu,3 Qun Wei,1 Tianyi Zhang,1 You Lang Zhou4 1Department of Gastroenterology, 2Department of General Surgery, Affiliated Hospital of Nantong University, 3Key Laboratory of Neuroregeneration, Nantong University, 4The Hand Surgery Research Center, Department of H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li F, Wang F, Zhu C, Wei Q, Zhang T, Zhou YL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	hepatocellular carcinoma nanoparticle miR-221 biomarker therapeutic target Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/49523b1a2b1d4066a9fb6d15ea5c340f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49523b1a2b1d4066a9fb6d15ea5c340f
record_format	dspace
spelling	oai:doaj.org-article:49523b1a2b1d4066a9fb6d15ea5c340f2021-12-02T04:23:40ZmiR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker1178-2013https://doaj.org/article/49523b1a2b1d4066a9fb6d15ea5c340f2018-04-01T00:00:00Zhttps://www.dovepress.com/mir-221-suppression-through-nanoparticle-based-mirna-delivery-system-f-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Feng Li,1,* Feiran Wang,2,* Changlai Zhu,3 Qun Wei,1 Tianyi Zhang,1 You Lang Zhou4 1Department of Gastroenterology, 2Department of General Surgery, Affiliated Hospital of Nantong University, 3Key Laboratory of Neuroregeneration, Nantong University, 4The Hand Surgery Research Center, Department of Hand Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People’s Republic of China *These authors contributed equally to this work Background: MicroRNA-221(miR-221) is frequently dysregulated in cancer. The purpose of this study was to explore whether miR-221 can be used as a potential diagnostic marker or therapeutic target for hepatocellular carcinoma (HCC). Methods: In this study, we investigated whether miR-221 expression was associated with clinicopathological characteristics and prognosis in HCC patients, and we developed a nanoparticle-based miRNA delivery system and detected its therapeutic efficacy in vitro and in vivo. Results: We found that miR-221 was upregulated in HCC tissues, cell lines and blood of HCC patients. Upregulated miR-221 was associated with clinical TNM stage and tumor capsular infiltration, and showed poor prognosis, suggesting that its suppression could serve as an effective approach for hepatocellular carcinoma therapy. Treatment of HCC cells with nanoparticle/miR-221 inhibitor complexes suppressed their growth, colony formation ability, migration and invasion. In vivo, the growth of the tumors treated by the nanoparticle/miR-221 inhibitor complexes were significantly less than those treated by the nanoparticle/miRNA scramble complexes. In addition, circulating miR-221 may act as a potential tumor biomarker for early diagnosis of HCC, and combined serum miR-221 and AFP detection gave a better performance than individual detection in early diagnosis of HCC. Conclusion: These findings suggest that a nanoparticle-based miRNA delivery system could potentially serve as a safe and effective treatment and miR-221 could also be a potential diagnostic marker for HCC. Keywords: hepatocellular carcinoma, nanoparticle, miR-221, biomarker, therapeutic targetLi FWang FZhu CWei QZhang TZhou YLDove Medical Pressarticlehepatocellular carcinomananoparticlemiR-221biomarkertherapeutic targetMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 2295-2307 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma nanoparticle miR-221 biomarker therapeutic target Medicine (General) R5-920
spellingShingle	hepatocellular carcinoma nanoparticle miR-221 biomarker therapeutic target Medicine (General) R5-920 Li F Wang F Zhu C Wei Q Zhang T Zhou YL miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
description	Feng Li,1,* Feiran Wang,2,* Changlai Zhu,3 Qun Wei,1 Tianyi Zhang,1 You Lang Zhou4 1Department of Gastroenterology, 2Department of General Surgery, Affiliated Hospital of Nantong University, 3Key Laboratory of Neuroregeneration, Nantong University, 4The Hand Surgery Research Center, Department of Hand Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People’s Republic of China *These authors contributed equally to this work Background: MicroRNA-221(miR-221) is frequently dysregulated in cancer. The purpose of this study was to explore whether miR-221 can be used as a potential diagnostic marker or therapeutic target for hepatocellular carcinoma (HCC). Methods: In this study, we investigated whether miR-221 expression was associated with clinicopathological characteristics and prognosis in HCC patients, and we developed a nanoparticle-based miRNA delivery system and detected its therapeutic efficacy in vitro and in vivo. Results: We found that miR-221 was upregulated in HCC tissues, cell lines and blood of HCC patients. Upregulated miR-221 was associated with clinical TNM stage and tumor capsular infiltration, and showed poor prognosis, suggesting that its suppression could serve as an effective approach for hepatocellular carcinoma therapy. Treatment of HCC cells with nanoparticle/miR-221 inhibitor complexes suppressed their growth, colony formation ability, migration and invasion. In vivo, the growth of the tumors treated by the nanoparticle/miR-221 inhibitor complexes were significantly less than those treated by the nanoparticle/miRNA scramble complexes. In addition, circulating miR-221 may act as a potential tumor biomarker for early diagnosis of HCC, and combined serum miR-221 and AFP detection gave a better performance than individual detection in early diagnosis of HCC. Conclusion: These findings suggest that a nanoparticle-based miRNA delivery system could potentially serve as a safe and effective treatment and miR-221 could also be a potential diagnostic marker for HCC. Keywords: hepatocellular carcinoma, nanoparticle, miR-221, biomarker, therapeutic target
format	article
author	Li F Wang F Zhu C Wei Q Zhang T Zhou YL
author_facet	Li F Wang F Zhu C Wei Q Zhang T Zhou YL
author_sort	Li F
title	miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
title_short	miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
title_full	miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
title_fullStr	miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
title_full_unstemmed	miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
title_sort	mir-221 suppression through nanoparticle-based mirna delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/49523b1a2b1d4066a9fb6d15ea5c340f
work_keys_str_mv	AT lif mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT wangf mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhuc mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT weiq mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhangt mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker AT zhouyl mir221suppressionthroughnanoparticlebasedmirnadeliverysystemforhepatocellularcarcinomatherapyanditsdiagnosisasapotentialbiomarker
_version_	1718401241818595328

miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker

Ejemplares similares